Literature DB >> 19812464

Correlation of clinical features with argyrophilic grains at autopsy.

Marwan N Sabbagh1, Sonny S Sandhu, Martin R Farlow, Linda Vedders, Holly A Shill, John N Caviness, Donald J Connor, Lucia Sue, Charles H Adler, Thomas G Beach.   

Abstract

Argyrophilic grains (AGs) are a pathologic feature found in association with neurodegenerative disease. Some have suggested that these features may occur as a distinctive condition. We reviewed 80 subjects from our tissue bank with pathologically confirmed AGs and identified their clinical features. We compared these subjects' features to the features of subjects with matched clinical diagnoses but without AGs. Subjects with AGs represented 21.7% of the entire autopsy sample from 1999 to 2005 (80 out of 367). Of Alzheimer disease (AD) subjects, 43 out of 233 had AGs (18.4% of AD subjects); 11 out of 42 Parkinson disease with dementia subjects had AGs (26.1% of Parkinson disease with dementia subjects); 2 out of 9 dementia with Lewy bodies subjects had AGs (22.2% of dementia with Lewy bodies subjects); 4 out of 15 mild cognitive impairment subjects had AGs (26.7% of mild cognitive impairment subjects); and 20 out of 68 cognitively normal subjects had AGs (29.4% of cognitively normal). Subjects with AGs tended to be older but only significantly so in AD. Many comorbid non-neurologic health conditions were seen in cases of AGs without any single predilection emerging. AGs occur in approximately 22% of the entire autopsy cohort and are likely associated with advanced age. No distinctive antemortem clinical features were over represented in the AG cases. AGs can occur with or without neurodegenerative conditions and can occur in the absence of significant cognitive decline. AGs are not clearly associated with any single comorbid health condition.

Entities:  

Mesh:

Year:  2009        PMID: 19812464      PMCID: PMC2760041          DOI: 10.1097/WAD.0b013e318199d833

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  29 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Staging of argyrophilic grains: an age-associated tauopathy.

Authors:  Yuko Saito; Nyoka N Ruberu; Motoji Sawabe; Tomio Arai; Noriko Tanaka; Yukio Kakuta; Hiroshi Yamanouchi; Shigeo Murayama
Journal:  J Neuropathol Exp Neurol       Date:  2004-09       Impact factor: 3.685

3.  Hippocampal sclerosis dementia with tauopathy.

Authors:  Thomas G Beach; Lucia Sue; Sarah Scott; Kathryn Layne; Amanda Newell; Douglas Walker; Matthew Baker; Naraju Sahara; Shu-Hui Yen; Michael Hutton; Richard Caselli; Charles Adler; Donald Connor; Marwan Sabbagh
Journal:  Brain Pathol       Date:  2003-07       Impact factor: 6.508

4.  Argyrophilic grain disease mimicking temporal Pick's disease: a clinical, radiological, and pathological study of an autopsy case with a clinical course of 15 years.

Authors:  K Tsuchiya; K Mitani; T Arai; S Yamada; T Komiya; Y Esaki; C Haga; H Yamanouchi; K Ikeda
Journal:  Acta Neuropathol       Date:  2001-08       Impact factor: 17.088

5.  Argyrophilic grain disease: neuropathology, frequency in a dementia brain bank and lack of relationship with apolipoprotein E.

Authors:  Takashi Togo; Natalie Cookson; Dennis W Dickson
Journal:  Brain Pathol       Date:  2002-01       Impact factor: 6.508

Review 6.  [Dynamic neuropathology of tauopathy].

Authors:  S Murayama
Journal:  Rinsho Shinkeigaku       Date:  2001-12

7.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

8.  Atypical late-onset dementia characterized by limbic degeneration with coiled bodies and argyrophilic threads.

Authors:  K Oshima; K Tsuchiya; T Arai; H Akiyama; S Iritani; K Niizato; M Matsushita; K Ikeda
Journal:  Clin Neuropathol       Date:  2003 Nov-Dec       Impact factor: 1.368

9.  A clinicopathologic study of 100 cases of Parkinson's disease.

Authors:  A J Hughes; S E Daniel; S Blankson; A J Lees
Journal:  Arch Neurol       Date:  1993-02

Review 10.  Dementia with Lewy bodies.

Authors:  Ian McKeith; Jacobo Mintzer; Dag Aarsland; David Burn; Helen Chiu; Jiska Cohen-Mansfield; Dennis Dickson; Bruno Dubois; John E Duda; Howard Feldman; Serge Gauthier; Glenda Halliday; Brian Lawlor; Carol Lippa; Oscar L Lopez; João Carlos Machado; John O'Brien; Jeremy Playfer; Wayne Reid
Journal:  Lancet Neurol       Date:  2004-01       Impact factor: 44.182

View more
  21 in total

1.  A quantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson disease.

Authors:  Richard A Armstrong; Paul T Kotzbauer; Joel S Perlmutter; Meghan C Campbell; Kyle M Hurth; Robert E Schmidt; Nigel J Cairns
Journal:  J Neural Transm (Vienna)       Date:  2013-08-31       Impact factor: 3.575

2.  Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP?

Authors:  Virgilio Gerald H Evidente; Charles H Adler; Marwan N Sabbagh; Donald J Connor; Joseph G Hentz; John N Caviness; Lucia I Sue; Thomas G Beach
Journal:  Parkinsonism Relat Disord       Date:  2011-03-21       Impact factor: 4.891

3.  Concomitant pathologies among a spectrum of parkinsonian disorders.

Authors:  Brittany N Dugger; Charles H Adler; Holly A Shill; John Caviness; Sandra Jacobson; Erika Driver-Dunckley; Thomas G Beach
Journal:  Parkinsonism Relat Disord       Date:  2014-02-22       Impact factor: 4.891

4.  Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.

Authors:  Brittany N Dugger; Christopher M Clark; Geidy Serrano; Monica Mariner; Barry J Bedell; R Edward Coleman; P Murali Doraiswamy; Ming Lu; Adam S Fleisher; Eric M Reiman; Marwan N Sabbagh; Carl H Sadowsky; Julie A Schneider; Simone P Zehntner; Alan P Carpenter; Abhinay D Joshi; Mark A Mintun; Michael J Pontecorvo; Daniel M Skovronsky; Lucia I Sue; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2014-01       Impact factor: 3.685

5.  Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi.

Authors:  Vanessa D Smith; Adam D Bachstetter; Eseosa Ighodaro; Kelly Roberts; Erin L Abner; David W Fardo; Peter T Nelson
Journal:  Brain Pathol       Date:  2017-03-24       Impact factor: 6.508

Review 6.  Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.

Authors:  David J Irwin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2013-07-31       Impact factor: 34.870

7.  Prominent psychiatric symptoms in patients with Parkinson's disease and concomitant argyrophilic grain disease.

Authors:  O Grau-Rivera; E Gelpi; M J Rey; F Valldeoriola; E Tolosa; Y Compta; M J Martí
Journal:  J Neurol       Date:  2013-09-18       Impact factor: 4.849

8.  A quantitative study of tau pathology in 11 cases of chronic traumatic encephalopathy.

Authors:  R A Armstrong; A C McKee; T D Stein; V E Alvarez; N J Cairns
Journal:  Neuropathol Appl Neurobiol       Date:  2016-04-15       Impact factor: 8.090

9.  TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies.

Authors:  Stacy J Arnold; Brittany N Dugger; Thomas G Beach
Journal:  Acta Neuropathol       Date:  2013-04-20       Impact factor: 17.088

10.  Higher Prevalence of TDP-43 Proteinopathy in Cognitively Normal Asians: A Clinicopathological Study on a Multiethnic Sample.

Authors:  Camila Nascimento; Claudia K Suemoto; Roberta D Rodriguez; Ana Tereza Di Lorenzo Alho; Renata P Leite; Jose Marcelo Farfel; Carlos Augusto Gonçalves Pasqualucci; Wilson Jacob-Filho; Lea T Grinberg
Journal:  Brain Pathol       Date:  2015-09-17       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.